InMune Bio posts results for Phase 2 XPro1595 trial in early Alzheimer's disease

This week's update centers on a single completed Phase 2 Alzheimer's trial sponsored by InMune Bio.

• The study, known as MINDFuL (NCT05318976), tested subcutaneous XPro1595, also known as INB03/XPro, XENP1595, or DN-TNF, delivered by weekly subcutaneous injection.¹ The trial was designed to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability¹ in patients with early Alzheimer's disease marked by inflammation biomarkers. The trial enrolled 207 participants¹ and reached completed¹ status, with primary and study completion both dated 2025-05-12 (actual) and results first posted 2026-06-29 (actual). The primary outcome measure was change from Baseline to Week 24 in the Early and Mild Alzheimer's Cognitive Composite (EMACC), a z-score composite of six neuropsychological tests¹.